RA
HQL

Reby Advisors’s abrdn Life Sciences Investors HQL Stock Holding History

Reby Advisors’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$50K Buy
+2,550
New +$47.1K 0.01% 226

Other funds holding HQL

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
MC
Matisse Capital Portland, Oregon $234M AUM 19.72% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Cohen & Steers
Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return

Reby Advisors's HQL Position: Q4 2020 in Review

Reby Advisors opened a new position in abrdn Life Sciences Investors (HQL) in Q4 2020: 2,550 shares worth $50K. The stake represents 0.01% of the portfolio and ranks #226 among its holdings.

66 funds tracked by Wall St. Rank hold HQL as of Q4 2020.

  • Reby Advisors held 2,550 shares of abrdn Life Sciences Investors worth $50K as of Q4 2020.
  • abrdn Life Sciences Investors was a new Reby Advisors position in Q4 2020.
  • abrdn Life Sciences Investors made up 0.01% of Reby Advisors's portfolio in Q4 2020, its #226 holding.
  • 66 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2020.

Based on Reby Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.